Also called personalized medicine, this evolving field makes use of an individual’s genes, lifestyle, environment and other factors to identify unique disease risks and guide treatment decision-making.
Masimo's MightySat Medical is the first FDA-cleared pulse oximeter available to consumers without a prescription, which could disrupt the market for the notoriously inaccurate at-home devices.
MediView’s technologies utilize AR to provide clinicians with 3D “X-ray vision” guidance during minimally invasive procedures and surgeries, while also offering remote collaboration.
Pittsburgh-based startup SpIntellx has been awarded a $225,000 research grant by the National Science Foundation to further develop its HistoMapr-Breast system—an AI that images whole-slide samples and acts as a computational guide for pathologists.
More than 10,000 nurses from Montefiore Medical Center, Mount Sinai Hospital and New York Presbyterian are set to strike April 2 after months of negotiation failed to yield safer nurse-to-patient ratios, the New York State Nurses Association has announced.
Cleveland Clinic this month announced it’s launching a Center for Clinical Artificial Intelligence (CCAI) dedicated to the development and application of AI in medicine.
French pharmaceutical startup Pharnext is leveraging AI and pleiotropy to develop new drug combinations and repurpose existing therapies, Fortune reported March 19.
A multitude of recent studies and success stories suggest artificial intelligence is on its way to topping doctors in accurately diagnosing diseases from asthma to breast cancer—seemingly a step in the right direction. But does the hype surrounding AI’s victories eclipse its shortcomings?
Artificial intelligence shows great promise in recognizing patterns, liberating physicians from keyboards and predicting outcomes, but where does it fall short? Medical guru Eric Topol does a deep dive into those topics and many more in his new book, Deep Medicine.
A deep neural network crafted by research specialists at Dartmouth’s Norris Cotton Cancer Center identified different types of lung adenocarcinoma as well as practicing pathologists in a recent study, according to work published March 4 in Scientific Reports.
A 14-week health technology “sprint” sponsored by the U.S. Census Bureau and coordinated by HHS has produced an AI tool that developers claim could revolutionize the way researchers match cancer patients with clinical trials.
